RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis

作者：Aksamit Timothy^*; De Soyza Anthony; Bandel Tiemo Joerg; Criollo Margarita; Elborn J Stuart; Operschall Elisabeth; Polverino Eva; Roth Katrin; Winthrop Kevin L; Wilson Robert

来源：European Respiratory Journal, 2018, 51(1): 1702053.

DOI：10.1183/13993003.02053-2017

We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous year and predefined sputum bacteria.
Patients were randomised 2: 1 to twice-daily ciprofloxacin DPI 32.5 mg or placebo in 14-or 28-day on/off treatment cycles for 48 weeks. Primary end-points were time to first exacerbation and frequency of exacerbations. Enrolling countries and a level split (0.049 and 0.001 for 14- and 28-day cycles, respectively) differed from RESPIRE 1.
Patients were randomised to ciprofloxacin DPI (14 days on/off (n=176) or 28 days on/off (n=171)) or placebo (14 days on/off (n=88) or 28 days on/off (n=86)). The exacerbation rate was low across treatment arms (mean +/- SD 0.6 +/- 0.9). Active treatment showed trends to prolonged time to first exacerbation (ciprofloxacin DPI 14 days on/off: hazard ratio 0.87, 95.1% CI 0.62-1.21; p=0.3965; ciprofloxacin DPI 28 days on/off: hazard ratio 0.71, 99.9% CI 0.39-1.27; p=0.0511) and reduced frequency of exacerbations (ciprofloxacin DPI 14 days on/off: incidence rate ratio 0.83, 95.1% CI 0.59-1.17; p=0.2862; ciprofloxacin DPI 28 days on/off: incidence rate ratio 0.55, 99.9% CI 0.30-1.02; p=0.0014), although neither achieved statistical significance. Ciprofloxacin DPI was well tolerated.
Trends towards clinical benefit were seen with ciprofloxacin DPI, but primary end-points were not met.

• 出版日期2018-1-1